BBIO - Bridgebio Pharma Inc Stock Price, Fair Value and News

29.80USD-0.29 (-0.96%)Delayed as of 20 May 2024, 10:03 am ET

Market Summary

USD29.80-0.29

Delayedas of 20 May 2024, 10:03 am

-0.96%

BBIO Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)
Losses in recent quarter

BBIO Stock Price

View Fullscreen

BBIO RSI Chart

BBIO Valuation

Market Cap

5.6B

Price/Earnings (Trailing)

-10.3

Price/Sales (Trailing)

48.09

Price/Free Cashflow

-9.31

BBIO Price/Sales (Trailing)

BBIO Profitability

Operating Margin

97.78%

Return on Equity

52.7%

Return on Assets

-64.37%

Free Cashflow Yield

-10.74%

BBIO Fundamentals

BBIO Revenue

Revenue (TTM)

107.9M

Rev. Growth (Yr)

100%

Rev. Growth (Qtr)

100%

BBIO Earnings

Earnings (TTM)

-546.7M

Earnings Growth (Yr)

74.67%

Earnings Growth (Qtr)

78.77%

Breaking Down BBIO Revenue

52 Week Range

12.7536.36

(Low)(High)

Last 7 days

3.5%

Last 30 days

20.6%

Last 90 days

-19.0%

Trailing 12 Months

115.5%

How does BBIO drawdown profile look like?

BBIO Financial Health

Current Ratio

5.54

Debt/Equity

-0.42

Debt/Cashflow

-1.39

BBIO Investor Care

Shares Dilution (1Y)

16.59%

Diluted EPS (TTM)

-3.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	79.3M	88.8M	98.4M	107.9M
2021	23.6M	39.0M	54.3M	69.7M
2020	0	0	24.4M	8.2M
2019	0	0	0	40.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Bridgebio Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2024	scott randal w.	sold	-85,000	34.00	-2,500	-
Feb 16, 2024	homcy charles j	sold (taxes)	-56,149	37.21	-1,509	-
Feb 16, 2024	homcy charles j	acquired	-	-	3,760	-
Feb 16, 2024	kumar neil	sold (taxes)	-1,783,180	37.21	-47,922	ceo and president
Feb 16, 2024	stephenson brian c	acquired	-	-	44,996	secretary, treasurer & cfo
Feb 16, 2024	stephenson brian c	sold (taxes)	-703,976	37.21	-18,919	secretary, treasurer & cfo
Feb 16, 2024	kumar neil	acquired	-	-	102,249	ceo and president
Feb 15, 2024	valantine hannah	sold	-110,041	37.75	-2,915	-
Feb 15, 2024	valantine hannah	acquired	24,631	8.45	2,915	-
Jan 16, 2024	valantine hannah	sold	-110,683	37.97	-2,915	-

Which funds bought or sold BBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Ikarian Capital, LLC	reduced	-40.39	-10,380,300	8,719,840	0.96%
May 16, 2024	COMERICA BANK	added	16,150	1,181,290	1,190,850	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-2.9	-2,446,190	7,098,490	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	7.27	-709,116	3,265,030	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-582,707	-	-%
May 16, 2024	COMERICA BANK	sold off	-100	-1,206	-	-%
May 15, 2024	GILDER GAGNON HOWE & CO LLC	added	12.9	-219,080	1,400,640	0.02%
May 15, 2024	Octagon Capital Advisors LP	reduced	-2.38	-7,198,720	21,334,800	2.56%
May 15, 2024	ADAR1 Capital Management, LLC	added	196	9,525,960	16,999,900	3.86%
May 15, 2024	SUPERSTRING CAPITAL MANAGEMENT LP	added	71.33	2,601,060	10,930,400	7.23%

Are Funds Buying or Selling BBIO?

Are funds buying BBIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BBIO

No. of Funds

Unveiling Bridgebio Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2024	kumar neil	5.59%	9,959,504	SC 13G/A
Feb 13, 2024	vanguard group inc	7.36%	12,800,294	SC 13G/A
Jan 29, 2024	blackrock inc.	5.8%	10,156,773	SC 13G/A
Jan 23, 2024	state street corp	2.92%	5,086,899	SC 13G/A
Nov 22, 2023	viking global investors lp	15.7%	25,120,991	SC 13D/A
Jul 20, 2023	viking global investors lp	15.7%	25,120,991	SC 13D/A
Feb 14, 2023	kumar neil	6.42%	9,823,908	SC 13G/A
Feb 09, 2023	vanguard group inc	7.09%	10,591,455	SC 13G/A
Feb 08, 2023	state street corp	5.92%	8,844,943	SC 13G
Feb 01, 2023	blackrock inc.	6.6%	9,834,401	SC 13G/A

Recent SEC filings of Bridgebio Pharma Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 06, 2024	424B5	Prospectus Filed

Peers (Alternatives to Bridgebio Pharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.91	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.68	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.3	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.27	14.48	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Bridgebio Pharma Inc News

Latest updates

Bridgebio Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4	2019Q3
Revenue	100.0%	211	106	-	-	108	60.00	13.00	2.00	54.00	27.00	0.00	8.00	17.00	27.00
Cost Of Revenue	-8.1%	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-
Costs and Expenses	64.7%	211	128	131	129	154	175	179	152	148	168	128	128	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	168	128	128	92.00	81.00
S&GA Expenses	111.5%	66.00	31.00	32.00	31.00	36.00	44.00	55.00	46.00	46.00	45.00	37.00	36.00	35.00	23.00
R&D Expenses	51.8%	141	93.00	91.00	93.00	108	108	122	104	102	123	90.00	92.00	57.00	55.00
EBITDA Margin	-	-	-	-	-	-	-	7.97*	10.11*	14.03*	23.26*	65.90*	7.19*	7.35*	1.66*
Interest Expenses	16.6%	23.00	20.00	20.00	20.00	20.00	20.00	15.00	11.00	11.00	10.00	11.00	11.00	3.00	2.00
EBT Margin	-	-	-	-	-	-	-	7.25*	9.30*	12.97*	21.40*	61.28*	6.57*	7.12*	1.58*
Net Income	74.7%	-36.16	-142	-140	-140	-2.56	-201	-152	-161	-102	-171	-135	-130	-84.15	-60.66
Net Income Margin	-28.3%	-5.06*	-3.95*	-4.49*	-5.04*	-5.82*	-7.78*	-8.41*	-10.47*	-13.81*	-	-	-	-	-
Free Cashflow	-52.6%	-220	-144	-94.04	-135	-32.85	-161	-136	-128	-94.00	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	55.4%	849	546	655	504	626	623	729	862	813	1,013	782	1,081	1,093	704	788	905	990	632	641	326	465
Current Assets	64.0%	783	478	588	433	553	549	642	771	716	889	640	910	945	643	745	862	925	569	558	307	445
Cash Equivalents	26.4%	475	376	505	302	407	377	483	470	372	394	180	378	471	356	367	541	757	364	414	294	436
Net PPE	-3.4%	11.00	12.00	12.00	13.00	14.00	15.00	16.00	17.00	17.00	30.00	28.00	26.00	23.00	20.00	16.00	16.00	16.00	6.00	3.00	2.00	2.00
Liabilities	-0.1%	1,886	1,889	1,849	1,853	1,839	1,868	1,859	1,877	1,854	1,878	1,517	1,537	1,481	596	569	578	538	156	116	114	88.00
Current Liabilities	-1.6%	141	144	106	110	97.00	121	119	141	103	135	96.00	132	95.00	96.00	76.00	93.00	65.00	60.00	40.00	39.00	33.00
Long Term Debt	-2.6%	435	446	442	440	436	431	-	-	434	431	103	103	91.00	92.00	93.00	93.00	92.00	92.00	75.00	75.00	55.00
LT Debt, Non Current	-100.0%	-	446	442	440	436	431	-	-	434	431	103	103	91.00	92.00	93.00	93.00	92.00	92.00	75.00	75.00	55.00
Shareholder's Equity	22.8%	-1,037	-1,343	-	-	-1,213	-1,243	-	-	-	-	-	-	-	106	216	326	449	474	522	211	377
Retained Earnings	-1.4%	-2,595	-2,560	-2,392	-2,215	-2,057	-1,918	-1,780	-1,643	-1,633	-1,436	-1,289	-1,133	-1,037	-888	-768	-652	-531	-440	-366	-306	-179
Additional Paid-In Capital	23.0%	1,821	1,481	1,460	1,128	1,107	939	917	893	868	842	821	800	767	1,021	1,007	993	987	848	826	469	494
Shares Outstanding	6.9%	187	175	174	161	160	151	148	146	146	144	147	143	-	-	-	-	-	-	-	-	-
Minority Interest	8.0%	12.00	11.00	12.00	12.00	12.00	11.00	10.00	12.00	-0.03	3.00	5.00	7.00	6.00	48.00	52.00	60.00	68.00	65.00	62.00	48.00	62.00
Float	-	-	-	-	2,075	-	-	-	977	-	-	-	5,000	-	-	-	0.00	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-75.9%	-219,537	-124,819	-145,226	-113,353	-144,322	-93,243	-135,163	-30,453	-160,635	-133,895	-121,561	-91,713	-150,765	-96,261	-131,684	-87,849	-83,920	-76,203	-49,996	-68,248	-59,140
Share Based Compensation	-53.9%	17,057	37,025	22,600	27,178	21,907	21,789	17,361	28,287	24,122	19,774	16,042	30,112	33,577	12,146	17,699	18,392	10,222	10,007	5,777	3,358	2,232
Cashflow From Investing	34574.2%	22,753	-66.00	37,682	4,119	12,298	17,965	146,857	149,702	138,623	21,800	58,968	458	-282,052	83,018	-45,050	-128,984	38,023	-16,901	-197,342	-583	-2,427
Cashflow From Financing	6280.6%	279,548	-4,523	307,040	-1,231	150,249	6,377	1,445	-20,796	-160	325,381	-135,456	-1,391	547,912	4,531	2,782	703	439,173	42,904	367,508	-9,969	-1,651
Dividend Payments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	997
Buy Backs	-	-	-	-	-	-	-	-	-	-	1,542	143,150	5,308	50,000	-	-	-	75,000	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BBIO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 211,120	$ 1,826
Operating costs and expenses:
Cost of revenue	598	651
Research and development	140,972	92,861
Selling, general and administrative	65,807	31,108
Restructuring, impairment and related charges	3,400	3,369
Total operating costs and expenses	210,777	127,989
Income (loss) from operations	343	(126,163)
Other expense, net:
Interest income	4,075	4,153
Interest expense	(23,471)	(20,121)
Loss on extinguishment of debt	(26,590)	0
Other income (expense), net	9,483	(601)
Total other expense, net	(36,503)	(16,569)
Net loss	(36,160)	(142,732)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests	944	2,576
Net loss attributable to common stockholders of BridgeBio	$ (35,216)	$ (140,156)
Net loss per share attributable to common stockholders of BridgeBio, basic	$ (0.2)	$ (0.92)
Net loss per share attributable to common stockholders of BridgeBio, diluted	$ (0.2)	$ (0.92)
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic	178,705,310	152,645,635
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted	178,705,310	152,645,635

BBIO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

Current assets:

Cash and cash equivalents

$ 475,222

$ 375,935

^[1]

Marketable securities

44,469

Investments in equity securities

58,949

^[1]

Receivables from licensing and collaboration agreements

235,494

1,751

^[1]

Restricted cash

131

16,653

^[1]

Prepaid expenses and other current assets

28,108

24,305

^[1]

Total current assets

783,424

477,593

^[1]

Property and equipment, net

11,414

11,816

^[1]

Operating lease right-of-use assets

8,052

8,027

^[1]

Intangible assets, net

25,721

26,319

^[1]

Other assets

20,722

22,625

^[1]

Total assets

849,333

546,380

^[1]

Current liabilities:

Accounts payable

4,728

10,655

^[1]

Accrued compensation and benefits

32,395

57,370

^[1]

Accrued research and development liabilities

40,933

29,765

^[1]

Operating lease liabilities, current portion

4,544

4,128

^[1]

Deferred revenue, current portion

13,957

6,096

^[1]

Accrued professional and other accrued liabilities

44,920

35,830

^[1]

Total current liabilities

141,477

143,844

^[1]

Term loan, net

434,717

446,445

^[1]

Operating lease liabilities, net of current portion

8,297

8,981

^[1]

Deferred revenue, net of current portion

19,890

3,727

^[1]

Other long-term liabilities

595

5,634

^[1]

Total liabilities

1,886,191

1,888,915

^[1]

Commitments and contingencies (Note 8)

Redeemable convertible noncontrolling interests

525

478

Stockholders’ equity (deficit):

Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding

Common stock, $0.001 par value; 500,000,000 shares authorized; 193,314,505 shares issued and 187,122,744 shares outstanding as of March 31, 2024, 181,274,712 shares issued and 175,082,951 shares outstanding as of December 31, 2023

193

181

^[1]

Treasury stock, at cost; 6,191,761 shares as of March 31, 2024 and December 31, 2023

(275,000)

^[1]

Additional paid-in capital

1,820,994

1,481,032

^[1]

Accumulated other comprehensive income

^[1]

Accumulated deficit

(2,595,717)

(2,560,501)

^[1]

Total BridgeBio stockholders' deficit

(1,049,528)

(1,354,257)

^[1]

Noncontrolling interests

12,145

11,244

^[1]

Total stockholders' deficit

(1,037,383)

(1,343,013)

^[1],[2]

Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit

849,333

546,380

^[1]

2029 Notes

Current liabilities:

Notes, net

737,392

736,905

^[1]

2027 Notes

Current liabilities:

Notes, net

$ 543,823

$ 543,379

^[1]

[1]	The condensed consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements as of that date.
[2]	The consolidated balances as of December 31, 2023 and 2022 are derived from the audited consolidated financial statements as of those dates.

About Bridgebio Pharma Inc

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

CEO	Dr. Neil Kumar Ph.D.
WEBSITE	bridgebio.com
INDUSTRY	Biotechnology
EMPLOYEES	392

Bridgebio Pharma Inc Frequently Asked Questions

What is the ticker symbol for Bridgebio Pharma Inc? What does BBIO stand for in stocks?

BBIO is the stock ticker symbol of Bridgebio Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bridgebio Pharma Inc (BBIO)?

As of Fri May 17 2024, market cap of Bridgebio Pharma Inc is 5.64 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BBIO stock?

You can check BBIO's fair value in chart for subscribers.

What is the fair value of BBIO stock?

You can check BBIO's fair value in chart for subscribers. The fair value of Bridgebio Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bridgebio Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bridgebio Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether BBIO is over valued or under valued. Whether Bridgebio Pharma Inc is cheap or expensive depends on the assumptions which impact Bridgebio Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BBIO.

What is Bridgebio Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BBIO's PE ratio (Price to Earnings) is -10.31 and Price to Sales (PS) ratio is 48.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BBIO PE ratio will change depending on the future growth rate expectations of investors.